[go: up one dir, main page]

DK3495358T3 - Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner - Google Patents

Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner Download PDF

Info

Publication number
DK3495358T3
DK3495358T3 DK18197550.9T DK18197550T DK3495358T3 DK 3495358 T3 DK3495358 T3 DK 3495358T3 DK 18197550 T DK18197550 T DK 18197550T DK 3495358 T3 DK3495358 T3 DK 3495358T3
Authority
DK
Denmark
Prior art keywords
amid
ifn
modulators
substituted heterocyclic
heterocyclic compounds
Prior art date
Application number
DK18197550.9T
Other languages
English (en)
Inventor
Amit Kumar
Ryan M Moslin
David S Weinstein
Stephen T Wrobleski
John S Tokarski
Douglas G Batt
Shuqun Lin
Steven H Spergel
Yanlei Zhang
Chunjian Liu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3495358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3495358T3 publication Critical patent/DK3495358T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18197550.9T 2012-11-08 2013-11-07 Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner DK3495358T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08
EP13811640.5A EP2922846B1 (en) 2012-11-08 2013-11-07 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha

Publications (1)

Publication Number Publication Date
DK3495358T3 true DK3495358T3 (da) 2022-05-23

Family

ID=49876960

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13811640.5T DK2922846T3 (da) 2012-11-08 2013-11-07 Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha
DK18197550.9T DK3495358T3 (da) 2012-11-08 2013-11-07 Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13811640.5T DK2922846T3 (da) 2012-11-08 2013-11-07 Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha

Country Status (40)

Country Link
US (6) USRE47929E1 (da)
EP (3) EP2922846B1 (da)
JP (3) JP6407159B2 (da)
KR (1) KR102195194B1 (da)
CN (1) CN104884454B (da)
AR (1) AR094452A1 (da)
AU (4) AU2013341186B2 (da)
BR (1) BR112015010102B1 (da)
CA (1) CA2890981C (da)
CL (1) CL2015001231A1 (da)
CY (3) CY1121188T1 (da)
DK (2) DK2922846T3 (da)
EA (1) EA028814B1 (da)
ES (2) ES2702148T3 (da)
FI (1) FIC20230028I1 (da)
FR (1) FR23C1030I2 (da)
HK (1) HK1215255A1 (da)
HR (2) HRP20220766T1 (da)
HU (3) HUE059409T2 (da)
IL (1) IL238610A0 (da)
LT (3) LT2922846T (da)
MA (1) MA38072A1 (da)
MX (2) MX2015005731A (da)
MY (2) MY175448A (da)
NL (1) NL301238I2 (da)
NO (1) NO2023032I1 (da)
NZ (1) NZ708859A (da)
PE (1) PE20150944A1 (da)
PH (1) PH12015501004A1 (da)
PL (2) PL2922846T3 (da)
PT (2) PT2922846T (da)
RS (2) RS63328B1 (da)
SG (3) SG11201503399XA (da)
SI (2) SI3495358T1 (da)
SM (2) SMT201900001T1 (da)
TR (1) TR201820824T4 (da)
TW (1) TWI605041B (da)
UY (1) UY35126A (da)
WO (1) WO2014074661A1 (da)
ZA (1) ZA201504052B (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015009798A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
UY35126A (es) * 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US9834548B2 (en) 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
RU2020124922A (ru) 2015-11-26 2020-08-10 Новартис Аг Новые производные диаминопиридина
IL265922B2 (en) 2016-10-14 2025-02-01 Nimbus Lakshmi Inc TYK2 inhibitors and their uses
IL266109B1 (en) 2016-10-21 2025-01-01 Nimbus Lakshmi Inc TYK2 inhibitors and their uses
CN110267964B (zh) * 2016-12-13 2022-05-03 百时美施贵宝公司 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AR111233A1 (es) 2017-03-08 2019-06-19 Nimbus Lakshmi Inc Inhibidores de tyk2, usos y métodos para la producción de los mismos
CN110475774B (zh) * 2017-03-30 2023-06-02 百时美施贵宝公司 用于制备Tyk2抑制剂的方法
KR102702228B1 (ko) * 2017-11-21 2024-09-02 브리스톨-마이어스 스큅 컴퍼니 술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물
JP6557436B1 (ja) 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド チロシンキナーゼ２媒介性シグナル伝達の阻害剤
WO2019183186A1 (en) * 2018-03-22 2019-09-26 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
CN112236425A (zh) * 2018-05-31 2021-01-15 百时美施贵宝公司 6-(环丙烷甲酰氨基)-4-((2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯基)氨基)-n-(甲基-d3)哒嗪-3-甲酰胺的结晶形式
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
EP3866789A4 (en) 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND THEIR USES
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
WO2020092196A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
US11053241B2 (en) 2018-11-30 2021-07-06 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
AU2020216914A1 (en) * 2019-01-30 2021-09-16 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
EP3962475A1 (en) * 2019-04-30 2022-03-09 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
US20220235039A1 (en) 2019-06-12 2022-07-28 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
WO2021011513A1 (en) 2019-07-16 2021-01-21 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
EP4007757A4 (en) * 2019-08-01 2023-07-19 Integral Biosciences Pvt. Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS AND THEIR USES
CN114945366B (zh) 2019-09-13 2025-01-07 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN119424435A (zh) * 2019-09-18 2025-02-14 百时美施贵宝公司 Tyk2抑制剂的剂型
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
US20230049130A1 (en) * 2020-01-19 2023-02-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Deucravacitinib crystal form, preparation method therefor and use thereof
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
HRP20240643T1 (hr) * 2020-03-11 2024-08-02 Beijing Innocare Pharma Tech Co., Ltd. Heterociklički spojevi za inhibiciju aktivnosti tyk2
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
US20230167092A1 (en) * 2020-04-28 2023-06-01 Bristol-Myers Squibb Company Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
CN113968846A (zh) * 2020-07-24 2022-01-25 上海翰森生物医药科技有限公司 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
JP2023534492A (ja) * 2020-07-24 2023-08-09 上▲海▼翰森生物医▲薬▼科技有限公司 ピリダジン誘導体遊離塩基の結晶形態、並びにその調製方法及びその使用
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN114057651A (zh) * 2020-07-31 2022-02-18 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
AU2021342517A1 (en) 2020-09-18 2023-05-11 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
WO2022100710A1 (en) * 2020-11-12 2022-05-19 Cullgen (Shanghai) , Inc. Tyrosine kinase 2 (tyk2) degradation compounds and methods of use
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
WO2022121868A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
EP4284796B1 (en) 2021-01-29 2025-04-16 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN114907326B (zh) * 2021-02-06 2025-02-18 正大天晴药业集团股份有限公司 含酰胺基和联环的tyk2抑制剂化合物
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
AU2022222472A1 (en) 2021-02-19 2023-09-28 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn Inc HPK1 ANTAGONISTS AND THEIR USES
US20240246944A1 (en) * 2021-03-16 2024-07-25 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
EP4313974A1 (en) 2021-03-29 2024-02-07 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN117177960B (zh) * 2021-03-30 2025-01-28 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
CN117136058A (zh) 2021-05-04 2023-11-28 上海喆邺生物科技有限公司 一类含氮杂环吡啶类化合物
CA3217332A1 (en) 2021-05-14 2022-11-17 Bristol-Myers Squibb Company Substituted heterocyclic compounds
JP2024518792A (ja) 2021-05-14 2024-05-02 ブリストル－マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
US20240317718A1 (en) 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
EP4337656A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CN115466289A (zh) 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用
TWI825800B (zh) * 2021-06-22 2023-12-11 大陸商南京明德新藥研發有限公司 亞磺醯亞胺類化合物及其應用
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
EP4387968A1 (en) 2021-08-20 2024-06-26 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
TW202313035A (zh) * 2021-08-21 2023-04-01 美商傳達治療有限公司 Ｊａｋ２抑制劑及其使用方法
KR20240065283A (ko) 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
US20240390369A1 (en) 2021-09-30 2024-11-28 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
KR20240090866A (ko) 2021-10-28 2024-06-21 브리스톨-마이어스 스큅 컴퍼니 듀크라바시티닙의 국소 제제
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
AU2022412835A1 (en) * 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
CN116283928A (zh) * 2021-12-20 2023-06-23 艾立康药业股份有限公司 一种哒嗪类化合物、其制备方法和应用
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN119233971A (zh) * 2022-05-31 2024-12-31 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
TW202416950A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 雜芳基甲醯胺及相關gpr84拮抗劑及其用途
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
WO2024102683A1 (en) 2022-11-08 2024-05-16 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2024127363A1 (en) 2022-12-16 2024-06-20 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
WO2024165000A1 (zh) * 2023-02-07 2024-08-15 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途
WO2024236491A1 (en) * 2023-05-15 2024-11-21 Glenmark Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
CN119080742A (zh) * 2023-06-05 2024-12-06 甘莱制药有限公司 脂质合成的杂环调节剂的工业化制备
WO2024257023A1 (en) 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN118593504B (zh) * 2024-06-03 2025-03-18 北京大学第三医院（北京大学第三临床医学院） 氘可来昔替尼或其盐在制备pvns药物方面的新用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
EP1184376B1 (en) * 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
EP1553982A4 (en) 2002-07-15 2008-03-26 Wyeth Corp METHOD AND COMPOSITIONS FOR MODULATING THE DEVELOPMENT AND FUNCTION OF T-HELPER CELLS (T sb H / sb)
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
BR112012023382A2 (pt) * 2010-03-17 2018-05-15 F Hoffmann La Roche Ag T compostos, composições e métodos de uso de imidazopiridina.
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
CA2817785A1 (en) 2010-11-19 2012-05-24 Toby Blench Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
JP6109192B2 (ja) * 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
KR20150068484A (ko) 2012-10-19 2015-06-19 에프. 호프만-라 로슈 아게 Syk 억제제
UY35126A (es) * 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
BR112015009798A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CN110475774B (zh) 2017-03-30 2023-06-02 百时美施贵宝公司 用于制备Tyk2抑制剂的方法

Also Published As

Publication number Publication date
HUE041750T2 (hu) 2019-05-28
US10000480B2 (en) 2018-06-19
MY175448A (en) 2020-06-29
NZ708859A (en) 2018-11-30
RS58187B1 (sr) 2019-03-29
SG10201706985UA (en) 2017-10-30
DK2922846T3 (da) 2019-01-21
LTPA2023523I1 (da) 2023-09-11
PL3495358T3 (pl) 2022-06-27
FR23C1030I2 (fr) 2024-10-25
WO2014074661A1 (en) 2014-05-15
ES2702148T3 (es) 2019-02-27
KR20150081339A (ko) 2015-07-13
US10526321B2 (en) 2020-01-07
IL238610A0 (en) 2015-06-30
CY2023017I1 (el) 2023-11-15
SMT202200258T1 (it) 2022-07-21
FR23C1030I1 (fr) 2023-10-13
CY1121188T1 (el) 2020-05-29
LT2922846T (lt) 2018-12-10
US20220356180A1 (en) 2022-11-10
US20180265504A1 (en) 2018-09-20
EP4071144A1 (en) 2022-10-12
EP3495358A1 (en) 2019-06-12
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
EP2922846A1 (en) 2015-09-30
AU2018267545B2 (en) 2020-04-02
US20200071315A1 (en) 2020-03-05
NL301238I2 (nl) 2023-10-04
BR112015010102B1 (pt) 2022-02-08
JP2018154636A (ja) 2018-10-04
JP6407159B2 (ja) 2018-10-17
PH12015501004B1 (en) 2015-07-27
JP6585231B2 (ja) 2019-10-02
AU2013341186B2 (en) 2017-03-30
MX2020003156A (es) 2020-07-29
CN104884454A (zh) 2015-09-02
EP2922846B1 (en) 2018-10-03
AU2017201076A1 (en) 2017-03-09
ZA201504052B (en) 2017-11-29
JP2020002157A (ja) 2020-01-09
TR201820824T4 (tr) 2019-01-21
EP3495358B8 (en) 2022-06-08
LT3495358T (lt) 2022-05-25
HUS2300025I1 (hu) 2023-08-28
CY2023017I2 (el) 2024-02-16
PL2922846T3 (pl) 2019-03-29
CA2890981C (en) 2022-07-05
HRP20181937T1 (hr) 2019-01-25
US9505748B2 (en) 2016-11-29
SI3495358T1 (sl) 2022-06-30
BR112015010102A2 (pt) 2017-07-11
CN104884454B (zh) 2017-11-28
MY194668A (en) 2022-12-12
SMT201900001T1 (it) 2019-02-28
PT2922846T (pt) 2018-12-19
EA028814B1 (ru) 2018-01-31
KR102195194B1 (ko) 2020-12-24
TW201422593A (zh) 2014-06-16
EA201590917A1 (ru) 2015-09-30
JP2016506369A (ja) 2016-03-03
HRP20220766T1 (hr) 2022-09-16
AU2017201076B2 (en) 2018-11-15
NO2023032I1 (en) 2023-08-25
HUE059409T2 (hu) 2022-11-28
US20170022192A1 (en) 2017-01-26
FIC20230028I1 (fi) 2023-08-28
MA38072A1 (fr) 2016-07-29
AU2018267545A1 (en) 2018-12-13
UY35126A (es) 2014-05-30
USRE47929E1 (en) 2020-04-07
SG11201503399XA (en) 2015-05-28
CL2015001231A1 (es) 2015-08-28
CY1125220T1 (el) 2025-03-28
AU2013341186A1 (en) 2015-07-02
US11021475B2 (en) 2021-06-01
PH12015501004A1 (en) 2015-07-27
AR094452A1 (es) 2015-08-05
AU2020203967B2 (en) 2020-10-22
US20150299183A1 (en) 2015-10-22
ES2914793T3 (es) 2022-06-16
MX2015005731A (es) 2015-09-16
HK1215255A1 (zh) 2016-08-19
PE20150944A1 (es) 2015-06-20
CA2890981A1 (en) 2014-05-15
SG10201706897TA (en) 2017-09-28
EP3495358B1 (en) 2022-04-27
AU2020203967A1 (en) 2020-07-16
SI2922846T1 (sl) 2019-04-30
PT3495358T (pt) 2022-06-02

Similar Documents

Publication Publication Date Title
DK3495358T3 (da) Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK3341367T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
DK2831079T3 (da) BICYKLISKE HETEROCYKLISKE DERIVATER SOM MNK1- og MNK2-MODULATORER OG ANVENDELSER DERAF
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK3321265T3 (da) 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
DK4082530T5 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK3060550T3 (da) Heteroarylforbindelser som btk-inhibitorer og anvendelser deraf
DK3366293T3 (da) Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
LT3239134T (lt) Piridonų amidai, kaip natrio kanalų moduliatoriai
DK3271358T3 (da) Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor
DK3536804T3 (da) Mikropeptider og anvendelse deraf til modulering af genekspression
DK2838533T3 (da) Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
DK3027186T3 (da) Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK2839004T3 (da) Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
DK3196194T3 (da) Pyrimidinderivater, der er nyttige som selektive jak3- og/eller jak1-inhibitorer
DK3082830T3 (da) Anvendelse af alginat-oligomerer som blod-antikoagulanter
DK3204380T3 (da) Hidtil ukendte aminopyridinforbindelser, der er anvendelige som hæmmere af proteinprenylering
DK3004080T3 (da) Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer
DK3280407T3 (da) Anvendelse af isothiocyanatderivater som modulatorer af perifere og neuropatiske smerter
DK2776447T4 (da) Fremgangsmåde til fremstilling af oxovinylionol og dets o-beskyttede derivater